Current Search:  Tumors--Immunological aspects. (x)

View All Items

  • CSV Spreadsheet
(1 - 3 of 3)
ELECTROCHEMICAL AND CHEMICAL REDUCTION OF A DIMERIC MOLYBDENUM(V)- CYSTEINE COMPLEX
Title
ELECTROCHEMICAL AND CHEMICAL REDUCTION OF A DIMERIC MOLYBDENUM(V)- CYSTEINE COMPLEX.
Creator
STEPHENSON, ROBERT FRANK., Florida Atlantic University
Abstract/Description
The reduction of Mo2O4 (cysteine)2^2-, a model complex for molybdenum redox enzymes, was studied using pr e parative and electrochemical techniques. Molybdenum(IV) complexes prepared were Mo2O3(cysteine)^4- and Mo2O3 (cysteine)2^2-. Electrochemical reduction of Mo2O4 (cysteine)2^2- produced the monomeric molybdenum(IV)-cysteine complex. The electrode reaction mechanism was found to be an ECE process and involved two one-electron reduction steps. The intermediate in this process was a Mo(V)/Mo...
Show moreThe reduction of Mo2O4 (cysteine)2^2-, a model complex for molybdenum redox enzymes, was studied using pr e parative and electrochemical techniques. Molybdenum(IV) complexes prepared were Mo2O3(cysteine)^4- and Mo2O3 (cysteine)2^2-. Electrochemical reduction of Mo2O4 (cysteine)2^2- produced the monomeric molybdenum(IV)-cysteine complex. The electrode reaction mechanism was found to be an ECE process and involved two one-electron reduction steps. The intermediate in this process was a Mo(V)/Mo(IV) mixed valence dimer, and its rate of dissociation into Mo(V) and Mo(IV) monomers was 50 sec^-1 at pH 9.2 and 22°C. Mo2O4 (cysteine)2^2- was observed to react with free cysteine at pH 8-10. This reaction was first order in Mo2O4 (cysteine)2^2- and first order in cysteine; the rate constant in pH 9.2 borate buffer was 10.9 ± 1.8 x 10^-3 M^-1 sec^-1 at 22°C. Cysteine was catalytically regenerated in this reaction. The reaction was formulated as a cysteine-catalyzed autooxidation-reduction of Mo2O4 (cysteine)2^2- yielding a molybdenum(IV)-cystine dimer as the product.
Show less
Date Issued
1971
PURL
http://purl.flvc.org/fcla/dt/13459
Subject Headings
Molybdenum compounds, Tumors--Immunological aspects
Format
Document (PDF)
A Study on Reversing the Immunosuppressive Phenotype of Tumor Associated Macrophages
Title
A Study on Reversing the Immunosuppressive Phenotype of Tumor Associated Macrophages.
Creator
Liddle, Genevieve M., Hartmann, James X., Florida Atlantic University, Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description
Extracellular stimuli may influence the M1/M2 phenotypic polarization of macrophages. We examined M1/M2 biomarkers, phagocytic activity, and tumoricidal activity in RAW 264.7 mouse macrophages. Macrophages were treated with conditioned media (CM) from 4T1 breast cancer cells, curcumin, 22-oxacalcitriol, LPS, or a combination of the previously listed. Arginase activity, a M2 phenotypic biomarker, was upregulated by the treatment of macrophages with conditioned media. Curcumin, 22-...
Show moreExtracellular stimuli may influence the M1/M2 phenotypic polarization of macrophages. We examined M1/M2 biomarkers, phagocytic activity, and tumoricidal activity in RAW 264.7 mouse macrophages. Macrophages were treated with conditioned media (CM) from 4T1 breast cancer cells, curcumin, 22-oxacalcitriol, LPS, or a combination of the previously listed. Arginase activity, a M2 phenotypic biomarker, was upregulated by the treatment of macrophages with conditioned media. Curcumin, 22- oxacalcitriol, and LPS partially inhibited RAW 264.7 arginase activity in the presence of 4T1 breast cancer media. 22-oxacalcitriol increased the phagocytic ability of RAW 264.7 macrophages in the presence of M2 polarizing substances produced by the 4T1 breast cancer cells. Also, LPS increased RAW 264.7 phagocytic ability in the presence of 4T1 breast cancer CM. This study looked at the potential substances that would possibly reverse the M2 tumor promoting macrophage phenotype seen in the breast cancer tumor environment.
Show less
Date Issued
2017
PURL
http://purl.flvc.org/fau/fd/FA00004867
Subject Headings
Macrophages., Breast--Cancer--Treatment., Tumors--Immunological aspects., Cancer--Immunological aspects., Biological response modifiers., Cancer--Molecular aspects.
Format
Document (PDF)
Bioinformatics mining of the dark matter proteome for cancer targets discovery
Title
Bioinformatics mining of the dark matter proteome for cancer targets discovery.
Creator
Delgado, Ana Paula, Narayanan, Ramaswamy, Florida Atlantic University, Charles E. Schmidt College of Science, Department of Biological Sciences
Abstract/Description
Mining the human genome for therapeutic target(s) discovery promises novel outcome. Over half of the proteins in the human genome however, remain uncharacterized. These proteins offer a potential for new target(s) discovery for diverse diseases. Additional targets for cancer diagnosis and therapy are urgently needed to help move away from the cytotoxic era to a targeted therapy approach. Bioinformatics and proteomics approaches can be used to characterize novel sequences in the genome...
Show moreMining the human genome for therapeutic target(s) discovery promises novel outcome. Over half of the proteins in the human genome however, remain uncharacterized. These proteins offer a potential for new target(s) discovery for diverse diseases. Additional targets for cancer diagnosis and therapy are urgently needed to help move away from the cytotoxic era to a targeted therapy approach. Bioinformatics and proteomics approaches can be used to characterize novel sequences in the genome database to infer putative function. The hypothesis that the amino acid motifs and proteins domains of the uncharacterized proteins can be used as a starting point to predict putative function of these proteins provided the framework for the research discussed in this dissertation.
Show less
Date Issued
2015
PURL
http://purl.flvc.org/fau/fd/FA00004361, http://purl.flvc.org/fau/fd/FA00004361
Subject Headings
Bioinformatics, Cancer -- Genetic aspects, Drug development -- Data processing, Genomics, Medical informatics, Proteomes -- Data processing, Tumors -- Immunological aspects
Format
Document (PDF)